Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2005 2
2006 1
2008 1
2009 1
2010 1
2011 1
2012 2
2013 2
2014 1
2015 2
2017 1
2018 3
2020 1
2021 3
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

22 results

Results by year

Filters applied: . Clear all
Page 1
Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer.
Robichaux JP, Elamin YY, Tan Z, Carter BW, Zhang S, Liu S, Li S, Chen T, Poteete A, Estrada-Bernal A, Le AT, Truini A, Nilsson MB, Sun H, Roarty E, Goldberg SB, Brahmer JR, Altan M, Lu C, Papadimitrakopoulou V, Politi K, Doebele RC, Wong KK, Heymach JV. Robichaux JP, et al. Among authors: estrada bernal a. Nat Med. 2018 May;24(5):638-646. doi: 10.1038/s41591-018-0007-9. Epub 2018 Apr 23. Nat Med. 2018. PMID: 29686424 Free PMC article.
ERBB family fusions are recurrent and actionable oncogenic targets across cancer types.
Schubert L, Elliott A, Le AT, Estrada-Bernal A, Doebele RC, Lou E, Borghaei H, Demeure MJ, Kurzrock R, Reuss JE, Ou SI, Braxton DR, Thomas CA, Darabi S, Korn WM, El-Deiry WS, Liu SV. Schubert L, et al. Among authors: estrada bernal a. Front Oncol. 2023 Apr 24;13:1115405. doi: 10.3389/fonc.2023.1115405. eCollection 2023. Front Oncol. 2023. PMID: 37168365 Free PMC article.
Dynamic adhesions and MARCKS in melanoma cells.
Estrada-Bernal A, Gatlin JC, Sunpaweravong S, Pfenninger KH. Estrada-Bernal A, et al. J Cell Sci. 2009 Jul 1;122(Pt 13):2300-10. doi: 10.1242/jcs.047860. Epub 2009 Jun 9. J Cell Sci. 2009. PMID: 19509053 Free PMC article.
Novel Human-Derived RET Fusion NSCLC Cell Lines Have Heterogeneous Responses to RET Inhibitors and Differential Regulation of Downstream Signaling.
Schubert L, Le AT, Estrada-Bernal A, Doak AE, Yoo M, Ferrara SE, Goodspeed A, Kinose F, Rix U, Tan AC, Doebele RC. Schubert L, et al. Among authors: estrada bernal a. Mol Pharmacol. 2021 Jun;99(6):435-447. doi: 10.1124/molpharm.120.000207. Epub 2021 Apr 1. Mol Pharmacol. 2021. PMID: 33795352 Free PMC article.
Resistance Mechanisms to Targeted Therapies in ROS1+ and ALK+ Non-small Cell Lung Cancer.
McCoach CE, Le AT, Gowan K, Jones K, Schubert L, Doak A, Estrada-Bernal A, Davies KD, Merrick DT, Bunn PA Jr, Purcell WT, Dziadziuszko R, Varella-Garcia M, Aisner DL, Camidge DR, Doebele RC. McCoach CE, et al. Among authors: estrada bernal a. Clin Cancer Res. 2018 Jul 15;24(14):3334-3347. doi: 10.1158/1078-0432.CCR-17-2452. Epub 2018 Apr 10. Clin Cancer Res. 2018. PMID: 29636358 Free PMC article.
ALK is a critical regulator of the MYC-signaling axis in ALK positive lung cancer.
Pilling AB, Kim J, Estrada-Bernal A, Zhou Q, Le AT, Singleton KR, Heasley LE, Tan AC, DeGregori J, Doebele RC. Pilling AB, et al. Among authors: estrada bernal a. Oncotarget. 2018 Jan 16;9(10):8823-8835. doi: 10.18632/oncotarget.24260. eCollection 2018 Feb 6. Oncotarget. 2018. PMID: 29507657 Free PMC article.
22 results